Joseph Goldstein - Regeneron Pharmaceuticals Independent Director

REGN -- USA Stock  

USD 286.15  1.09  0.38%

Dr. Joseph L.Goldstein, M.D., is an Independent Director of the Company. Dr. Goldstein was a Professor of Molecular Genetics and Internal Medicine and the Chairman of the Department of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences, the National Academy of Medicine, and the Royal Society of London. He also serves on the Boards of Trustees of The Rockefeller University and the Howard Hughes Medical Institute. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988.
Age: 77  Director Since 1991  Ph.D    
Goldstein extensive research experience, his distinguished scientific and academic credentials, including his receipt of the Nobel Prize for Physiology or Medicine in 1985, and his substantial understanding of the Company gained through his service as a director since 1991, led to the board decision to nominate Dr. Goldstein for reelection to the board.

Joseph Goldstein Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Terrence KearneyVertex Pharmaceuticals Incorpor
Margaret McGlynnVertex Pharmaceuticals Incorpor
David BullockOrigin Agritech Limited
Lloyd CarneyVertex Pharmaceuticals Incorpor
Bruce CarterDr Reddys Laboratories Ltd
William DoyleZoetis
Geoffrey ParkerPerrigo Company plc
Theodore SamuelsPerrigo Company plc
Frank DAmelioZoetis
Leo PuriDr Reddys Laboratories Ltd
Allan ObermanDr Reddys Laboratories Ltd
Shlomo YanaiPerrigo Company plc
Ashok GangulyDr Reddys Laboratories Ltd
Prasad MenonDr Reddys Laboratories Ltd
Gary CohenPerrigo Company plc
Shikha SharmaDr Reddys Laboratories Ltd
Geoffery MerszeiOrigin Agritech Limited
Adriana KaraboutisPerrigo Company plc
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
Yingqi XiaOrigin Agritech Limited
William SteereZoetis

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Purchased few shares of
few hours ago
Traded for 188.14
Purchased a lot of shares of
few hours ago
Traded for 150.35
Purchased few shares of
few hours ago
Traded for 175.29
Purchased a lot of shares of
few hours ago
Traded for 152.77
Purchased over 300 shares of
few hours ago
Traded for 9.25
Additionally take a look at Your Equity Center. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.